A Phase 3 interventional study of Technosphere Insulin and Active comparator in Diabetes, Type I, sponsored by Mannkind Corporation. Completed at 129 sites in 10 countries. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-10-16.
Sponsored by Mannkind Corporation · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 35 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 1 — 1 open to participants now, 1 under way, none of them phase 3. Insulin, Regular, Human · Diabetes Mellitus, Type 1.
Among the 35 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 1, this one is the 2nd largest by enrollment, is one of 4 that started in 2006, is one of 17 in phase 3, and was the 2nd registered.
3,756 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →1 of the 35 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 1 is open now, in 1 country. Recruiting first, the newest first:
Mannkind Corporation · Sites in United States
Ages 6–17
By country, each count listing its studies:
Insulin, Regular, Human: first FDA approval 1982 (HUMULIN R PEN), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →
Of the 416 Diabetes Mellitus, Type 1 studies recruiting now, 129 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
35 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 9 · Phase 3 17 · Phase 4 4
First in 1989; this study’s year is marked. 4 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 589 is above the median of 40 across 2,822 interventional studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 74 across the 35 interventional studies. Of the 34 that completed or were terminated, 10 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
31 of 35 have an industry lead sponsor. The 10 most frequent:
Mannkind Corporation is the lead sponsor of 57 studies on the registry; 3 are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 3 (38%) have results posted.
21 studies in Diabetes Mellitus, Type 1 by Mannkind Corporation: 1 open now, 1 under way, none of them phase 3. Of 19 finished, 10 (53%) have results posted.
Among the 21 studies in Diabetes Mellitus, Type 1 by Mannkind Corporation, this one is the 2nd largest by enrollment of the 18 interventional ones that give a count, is one of 2 that started in 2006, is one of 7 in phase 3, and was the 1st registered.
Mannkind Corporation’s Diabetes Mellitus, Type 1 studies by the year they started, since 2005.
1 of the studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 1 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07224321Mannkind CorporationINHALE-1st: Afrezza® For Youth With Newly-Diagnosed Type 1 Diabetes | 2027-03 |
Add it to your calendar (.ics) → With an account.
Among the 35 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 1, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Mannkind Corporation’s 21 in Diabetes Mellitus, Type 1:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To determine the safety and efficacy of inhaled insulin in the treatment of type 1 diabetes
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Technosphere Insulin
Drug: Technosphere Insulin
Rapid-acting analogue insulin plus basal insulin glargine
Drug: Active comparator
Inhalation, 15U/30U
sc injectable insulin
Compare the Mean Change From Baseline to Week 52 in HbA1c
Time frame: Baseline to Week 52
Change From Baseline in Weight to Week 52
Change from baseline in weight at Week 52
Time frame: Baseline to Week 52
Change From Baseline in Fasting Plasma Glucose to Week 52
Change from baseline in fasting plasma glucose at Week 52
Time frame: Baseline to Week 52
Number of Subjects Achieving Week 52 HbA1c Levels Less Than or Equal to 7.0%
Number of subjects achieving week 52 HbA1c levels less than or equal to 7.0%
Time frame: Baseline to Week 52
Incidence of Total Hypoglycemia
Defined as hypoglycemic symptoms that are relieved with carbohydrate intake or blood glucose measurement \<= 63 mg/dL, regardless of symptoms.
Time frame: Baseline to Week 52
Incidence of Severe Hypoglycemia
Severe hypoglycemia occurs when all 3 of the following occur simultaneously: * Subject requires the assistance of another person; * Subject exhibits at least 1 cognitive neurological symptom (memory loss, confusion, uncontrollable behavior, irrational behavior, unusual difficulty in awakening, seizure, loss of consciousness); * Measured BG is ≤ 49 mg/dL (2.7 mmol/L), or, in the absence of a BG measurement, clinical symptoms are reversed by oral carbohydrates, sc glucagon or intravenous glucose administration; OR, * Measured BG is ≤ 36 mg/dL (2.0 mmol/L) with or without symptoms.
Time frame: Baseline to Week 52
Total Hypoglycemia Event Rate
Number of Hypoglycemic Events/Total Subject Exposure Time (in months)
Time frame: Baseline to Week 52
Severe Hypoglycemia Event Rate
Number of Severe Hypoglycemic Events/Total Subject Exposure Time (in months)
Time frame: Baseline to Week 52
First Patient enrolled Feb, 2006 Multi-national trial conducted in US, Canada, Mexico, Brazil, Argentina, Chile, Spain, UK, Poland, Russia
| Milestone | TI + Insulin Glargine | Insulin Aspart + Insulin Glargine |
|---|---|---|
| Started | 301 | 288 |
| Completed | 198 | 220 |
| Not completed | 103 | 68 |
| Withdrew: Adverse event | 17 | 2 |
| Withdrew: Lost to follow-up | 5 | 5 |
| Withdrew: Physician decision | 15 | 7 |
| Withdrew: Protocol violation | 3 | 14 |
| Withdrew: Withdrawal by subject | 47 | 19 |
| Withdrew: Various | 7 | 5 |
| Withdrew: Randomized but not dosed | 8 | 16 |
| Withdrew: Other | 1 | 0 |
| Percentage | TI + Insulin Glargine | Insulin Aspart + Insulin Glargine |
|---|---|---|
| Compare the Mean Change From Baseline to Week 52 in HbA1c | -0.13 ± 0.058 | -0.37 ± 0.059 |
Change from baseline in weight at Week 52
| kilogram | TI + Insulin Glargine | Insulin Aspart + Insulin Glargine |
|---|---|---|
| Change From Baseline in Weight to Week 52 | -0.5 ± 0.32 | 1.4 ± 0.30 |
Change from baseline in fasting plasma glucose at Week 52
| mg/dl | TI + Insulin Glargine | Insulin Aspart + Insulin Glargine |
|---|---|---|
| Change From Baseline in Fasting Plasma Glucose to Week 52 | -46.5 ± 5.61 | -25.7 ± 5.23 |
Number of subjects achieving week 52 HbA1c levels less than or equal to 7.0%
| Participants | TI + Insulin Glargine | Insulin Aspart + Insulin Glargine |
|---|---|---|
| Number of Subjects Achieving Week 52 HbA1c Levels Less Than or Equal to 7.0% | 33 | 35 |
Defined as hypoglycemic symptoms that are relieved with carbohydrate intake or blood glucose measurement \<= 63 mg/dL, regardless of symptoms.
| percentage of participants | TI + Insulin Glargine | Insulin Aspart + Insulin Glargine |
|---|---|---|
| Incidence of Total Hypoglycemia | 85.67 | 92.28 |
Severe hypoglycemia occurs when all 3 of the following occur simultaneously: * Subject requires the assistance of another person; * Subject exhibits at least 1 cognitive neurological symptom (memory loss, confusion, uncontrollable behavior, irrational behavior, unusual difficulty in awakening, seizure, loss of consciousness); * Measured BG is ≤ 49 mg/dL (2.7 mmol/L), or, in the absence of a BG measurement, clinical symptoms are reversed by oral carbohydrates, sc glucagon or intravenous glucose administration; OR, * Measured BG is ≤ 36 mg/dL (2.0 mmol/L) with or without symptoms.
| percentage of participants | TI + Insulin Glargine | Insulin Aspart + Insulin Glargine |
|---|---|---|
| Incidence of Severe Hypoglycemia | 32.08 | 36.40 |
Number of Hypoglycemic Events/Total Subject Exposure Time (in months)
| Number of events/subject-month | TI + Insulin Glargine | Insulin Aspart + Insulin Glargine |
|---|---|---|
| Total Hypoglycemia Event Rate | 1.81 | 1.86 |
Number of Severe Hypoglycemic Events/Total Subject Exposure Time (in months)
| Number of events/subject-month | TI + Insulin Glargine | Insulin Aspart + Insulin Glargine |
|---|---|---|
| Severe Hypoglycemia Event Rate | 0.08 | 0.10 |
Collected over From first dose to 30 days after last dose. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| TI + Insulin Glargine | — | 52/293 (17.7%) | 265/293 (90.4%) |
| Insulin Aspart + Insulin Glargine | — | 47/272 (17.3%) | 257/272 (94.5%) |
| Event | TI + Insulin Glargine | Insulin Aspart + Insulin Glargine |
|---|---|---|
| HypoglycaemiaMetabolism and nutrition disorders | 30/293 | 34/272 |
| Loss of consciousnessNervous system disorders | 8/293 | 7/272 |
| Diabetic ketoacidosisMetabolism and nutrition disorders | 5/293 | 0/272 |
| Hypoglycaemic seizureMetabolism and nutrition disorders | 2/293 | 4/272 |
| KetoacidosisMetabolism and nutrition disorders | 3/293 | 0/272 |
| Ankle fractureInjury, poisoning and procedural complications | 1/293 | 2/272 |
| Gastrooesophageal reflux diseaseGastrointestinal disorders | 0/293 | 2/272 |
| Road traffic accidentInjury, poisoning and procedural complications | 1/293 | 2/272 |
| Acute myocardial infarctionCardiac disorders | 0/293 | 1/272 |
| Angina pectorisCardiac disorders | 0/293 | 1/272 |
| Event | TI + Insulin Glargine | Insulin Aspart + Insulin Glargine |
|---|---|---|
| HypoglycaemiaMetabolism and nutrition disorders | 252/293 | 252/272 |
| CoughRespiratory, thoracic and mediastinal disorders | 98/293 | 21/272 |
| Upper respiratory tract infectionInfections and infestations | 46/293 | 41/272 |
| NasopharyngitisInfections and infestations | 37/293 | 38/272 |
| InfluenzaInfections and infestations | 23/293 | 19/272 |
| HeadacheNervous system disorders | 16/293 | 15/272 |
| Pharyngolaryngeal painRespiratory, thoracic and mediastinal disorders | 16/293 | 6/272 |
| Pulmonary function test decreasedInvestigations | 16/293 | 4/272 |
ITT Population (589 were randomized - 24 Subjects randomized but never dosed)
| Age, Continuous(years) | TI + Insulin Glargine | Insulin Aspart + Insulin Glargine | Total |
|---|---|---|---|
| Mean | 37.9 ± 13.06 | 38.1 ± 13.18 | 38 ± 13.11 |
| Sex: Female, Male(Participants) | TI + Insulin Glargine | Insulin Aspart + Insulin Glargine | Total |
|---|---|---|---|
| Female | 139 | 132 | 271 |
| Male | 154 | 140 | 294 |
| HbA1c(percent) | TI + Insulin Glargine | Insulin Aspart + Insulin Glargine | Total |
|---|---|---|---|
| Mean | 8.4 ± 0.95 | 8.5 ± 0.97 | 8.5 ± 0.96 |
| Weight(kilogram) | TI + Insulin Glargine | Insulin Aspart + Insulin Glargine | Total |
|---|---|---|---|
| Mean | 76.7 ± 15.64 | 76.8 ± 14.95 | 76.7 ± 15.3 |
Showing the first 100 of 129 sites across 10 countries. Choose a country and city above to see the rest.
The record gives a start of Feb 2006, a primary completion of Jul 2008 and a completion of Aug 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2014, 6 years 3 months after primary completion. A results delay was requested in Jun 2009.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Insulin, Regular, Human